![](/img/cover-not-exists.png)
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
Barbara Pro, Brian Leber, Mitchell Smith, Luis Fayad, Jorge Romaguera, Fredrick Hagemeister, Alma Rodriguez, Peter McLaughlin, Felipe Samaniego, James Zwiebel, Adriana Lopez, Larry Kwak, Anas YounesVolume:
143
Year:
2008
Language:
english
Pages:
6
DOI:
10.1111/j.1365-2141.2008.07353.x
File:
PDF, 168 KB
english, 2008